Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement

Journal of Rheumatology

Volumn 31, Issue 12, 2004, Pages 2374-2381

  Hornung, Nete ^a,b   Ellingsen, Torkell ^b   Stengaard Pedersen, Kristian ^b   Poulsen, Jørgen H ^c  

^a RANDERS REGIONAL HOSPITAL   (Denmark)

^b Department of Rheumatology ^*  (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Erythrocyte; Folic acid; Methotrexate; Rheumatoid arthritis

Indexed keywords

COBALAMIN; CORTICOSTEROID; FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL;

ADULT; ALOPECIA; ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SELF ADMINISTRATION; ERYTHROCYTE; FEMALE; FLU LIKE SYNDROME; FOLATE METABOLISM; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RHEUMATOID ARTHRITIS; STOMATITIS;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; MALE; METHOTREXATE; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VITAMIN B 12;

EID: 10044236724     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
2. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001;8:123-43.
3. O'Dell JR. Methotrexate use in rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:779-96.
4. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues [editorial]. J Rheumatol 1994;1:1-5.
5. Van Ede AE, Laan RFJM, Blom HJ, De Abreu RA, van de Putte LBA. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
6. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
7. Ortiz Z, Shea B, Suarez-Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 2, 1999. Oxford: Update Software; 1999.
8. Griffith SM, Fisher J, Clarke S, et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology 2000;39:1102-9.
9. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
10. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43.
11. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993;36:795-803.
12. Van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
13. Weinblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993;20:950-2.
14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15:1480-8.
16. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
17. Kamen BA, Takach PL, Vatev R, Caston JD. A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 1976;70:54-63.
18. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
19. van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002;41:658-65.
20. Roubenoff R, Dellaripa P, Nadeau MR, et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 1997;40:718-22.
21. Hernanz A, Plaza A, Martin-Mola E, De Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999;32:65-70.
22. Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84.
23. Morgan SL, Baggott JE, Refsum H, Ueland PM. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther 1991;50:547-56.
24. Jensen OK, Rasmussen C, Mollerup F, et al. Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation. J Rheumatol 2002;29:1615-8.
25. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25:441-6.
26. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol 2001;30:305-7.
27. Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000;355:1616-7.
28. Quinlivan EP, McPartlin J, McNulty H, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002;359:227-8.
29. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
30. Boers GHJ. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000;26:291-5.
31. Leeb BF, Witzmann G, Ogris E, et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995;13:459-63.
32. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998;316:894-8.
33. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832-5.
34. Sandoval DM, Alarcon GS, Morgan SL. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol 1995;34:49-56.
35. Fathi NH, Mitros F, Hoffman J, et al. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 2002;29:2092-8.
36. Shiroky J, Neville C. Leucovorin for methotrexate induced elevations in liver transaminases [abstract]. Arthritis Rheum 1990;33 Suppl:R34.
37. Shiroky JB. The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin North Am 1997;23:969-80.
38. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
39. Stewart KA, Mackenzie AH, Clough JD, Wilke WS. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin Arthritis Rheum 1991;20:332-8.
40. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991;50:913-4.